Brokerages Set Alto Neuroscience, Inc. (NYSE:ANRO) Target Price at $23.83

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $23.8333.

ANRO has been the topic of a number of recent research reports. Jefferies Financial Group boosted their price target on shares of Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Robert W. Baird lifted their price objective on shares of Alto Neuroscience from $16.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Wall Street Zen upgraded shares of Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. HC Wainwright raised their price target on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Finally, Chardan Capital upgraded shares of Alto Neuroscience to a “strong-buy” rating in a research note on Wednesday, November 19th.

Institutional Investors Weigh In On Alto Neuroscience

Several large investors have recently bought and sold shares of ANRO. SCS Capital Management LLC acquired a new stake in Alto Neuroscience in the 1st quarter valued at about $144,000. Nuveen LLC purchased a new stake in shares of Alto Neuroscience during the first quarter worth approximately $302,000. Peapod Lane Capital LLC purchased a new stake in shares of Alto Neuroscience during the second quarter worth approximately $613,000. AWM Investment Company Inc. raised its holdings in Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock valued at $1,948,000 after acquiring an additional 214,153 shares in the last quarter. Finally, AlphaCore Capital LLC lifted its stake in Alto Neuroscience by 100.0% in the second quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after acquiring an additional 10,000 shares during the last quarter.

Alto Neuroscience Stock Down 1.7%

NYSE:ANRO opened at $12.82 on Wednesday. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $16.49. The stock’s fifty day moving average is $10.09 and its two-hundred day moving average is $5.51. The stock has a market capitalization of $398.32 million, a price-to-earnings ratio of -5.60 and a beta of 2.95. The company has a quick ratio of 15.42, a current ratio of 15.42 and a debt-to-equity ratio of 0.20.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. Research analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.